Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers.

ABSTRACT: Gastrointestinal (GI) cancers account for a large proportion of cancer deaths worldwide and pose a major public health challenge. Immunotherapy is considered to be one of the prominent and successful approaches in cancer treatment in recent years. Among them, immune checkpoint inhibitor (ICI) therapy, has received widespread attention, and many clinical findings support the feasibility of ICIs, with sustained responses and significantly prolonged lifespan observed in a wide range of tumors. However, patients treated with ICIs have not fully benefited, and therefore, the identification and development of biomarkers for predicting ICI treatment response have received further attention and exploration. From tumor genome to molecular interactions in the tumor microenvironment, and further expa

SUBMITTER: Li M 

PROVIDER: S-EPMC8790411 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature